Public health agency the US Food and Drug Administration announced on Monday that it has approved the new antibiotic Xenleta (lefamulin) for the treatment of adults with community-acquired bacterial pneumonia under its Qualified Infectious Disease Product (QIDP) designation.
The agency granted the approval of Xenleta to Nabriva Therapeutics.
Community-acquired pneumonia occurs when someone develops pneumonia in the community (not in a hospital). Pneumonia is a type of lung infection that can range in severity from mild to severe illness and can affect people of all ages.
In conjunction, the safety and efficacy of the company's Xenleta, taken either orally or intravenously, was evaluated in two clinical trials with a total of 1,289 patients with CABP.
In both the trials, the treatment with the company's Xenleta was compared to another antibiotic, moxifloxacin with or without linezolid. The patients treated with Xenleta had similar rates of clinical success as those treated with moxifloxacin with or without linezolid.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review